<DOC>
	<DOCNO>NCT01636726</DOCNO>
	<brief_summary>The study describe protocol perform within framework PROTECT ( Pharmacoepidemiological Research Outcomes Therapeutics European ConsorTium ) Work Package 2 Workgroup 1 . Primary aim study develop , test disseminate methodological standard design , conduct analysis Pharmacoepidemiological ( PE ) study applicable different safety issue use different data source . To achieve , result PE study five key adverse event ( AEs ) perform different database evaluate . Therefore , emphasis methodological aspect study protocol clinical consequence association investigation . Asthma chronic obstructive pulmonary disease ( COPD ) common chronic airway disease western world . For , stepwise treatment reduce symptom , improve lung function , prevent risk exacerbation recommend use several drug class accord guideline publish e.g . Global Initiative Asthma [ GINA guideline ] Global Initiative Chronic Obstructive Lung Disease [ GOLD guideline ] , respectively . Beta-2-adrenoceptor agonist ( B2A ) therapeutic mainstay treat asthma COPD due bronchodilative effect mediate B2A . This drug class consist two type drug : short act B2A ( SABA ) use reliever medication long act B2A ( LABA ) use maintenance / controller medication . Formoterol salmeterol frequently use LABA compound half-life 5-15 hr therefore , compound commonly labelled indication use twice day . . Focussing cardiac side effect B2A one must consider drug opposite mechanism action ( beta-adrenoceptor-antagonists ) well-known cardio protective effect widely use patient suffer e.g . ischemic heart disease , hypertension acute myocardial infarction ( AMI ) ) . Conversely , stimulation cardiac beta-adrenoceptor do B2A may deleterious cardiovascular effect particularly patient cardiac risk factor . And fact , tachycardia arrhythmias well-known side effect B2A confirm cardiac influence drug particularly oral therapy ( due high systemic exposure ) state respective summary product characteristic ( SPCs ) , e.g . clenbuterol ( Spiropent ( R ) ) . Obviously , inhale drug cause much small systemic exposure cardiac side effect ( e.g . arrhythmia , tachycardia ) also describe respective SPCs ( e.g . formoterol [ Foradil ( R ) ) . Furthermore , cardiac side also report exposure inhale MA ( e.g . ipratropium [ Atrovent ( R ) ] . Several observational study perform association usage inhale B2A occurrence AMI . However , study produce conflict result . Reasons variation numerous , e.g . small number event ( AMI ) lead poor precision risk estimate , potential misclassification potential cardiac event versus airway-related event due similar clinical complaint , difference population drug user , measurement drug exposure , background risk AMI . Additionally , consensus document release 2000 , redefine AMI . To make compare result possible , protocol give guideline conduct study way five database across 3 design ( cohort , nest case-control , case-cross-over ) association inhale LABA use AMI . The main focus evaluate impact study design , population database characteristic association inhale LABA AMI . Data collect follow database : The Health Improvement Network ( THIN ) , General Practice Research Database ( GPRD ) , Dutch Mondriaan project , Base de Datos para la Investigación Farmacoepidemiológica en Atencion Primaria ( BIFAP ) , National Databases Denmark , Bavarian statutory health insurance physician ' association database .</brief_summary>
	<brief_title>WEUKBRE5554 : IMI PROTECT ( Work Package 2 ) : Beta2 Agonists Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>For descriptive sudy : patient least one document valid data record period Jan 1 , 2002 Dec 31 , 2009 patient diagnosis asthma and/or COPD For cohort nest casecontrol study : patient least one document valid data record period Jan 1 , 2002 Dec 31 , 2009 patient diagnosis asthma and/or COPD patient least one prescription LABA/LAMA/SABA/SAMA Exclusion criterion : For cohort nest casecontrol study : patient AMI within 1 year index date</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>COPD</keyword>
	<keyword>AMI</keyword>
	<keyword>Asthma</keyword>
	<keyword>LABAs</keyword>
</DOC>